Side-by-side · Research reference
EpitalonvsThymosin α-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft8/37 cited
BPhase 3Reviewed8/39 cited
Epitalon
Pineal bioregulator · Telomerase activator
SQ or IM · Abdomen · Daily for 10–20 days
Thymosin α-1
Immune modulator · Approved (some countries)
SQ · 2× weekly · 6+ months for chronic indications
01Mechanism of Action
Parameter
Epitalon
Thymosin α-1
Primary target
Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003
Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001
Pathway
Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003
TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007
Downstream effect
Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003
Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007
Feedback intact?
—
—
Origin
Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003
Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001
Antibody development
—
—
02Dosage Protocols
Parameter
Epitalon
Thymosin α-1
Standard dose
5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003
Anecdotal community protocol. Russian clinical literature uses similar cycling.
—
Frequency
Once daily during a cycle
2× weekly (Mon/Thu typical)
Lower / starter dose
2.5 mg / day
0.8 mg per injection
Evidence basis
In-vitro telomerase + Russian clinical trialsKhavinson 2003
Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007
Duration
10–20 day cycles, 1–2× per year
6–12 months for chronic indications
Reconstitution
Bacteriostatic water
Sterile water for injection per vial label
Timing
Pre-sleep preferred (pineal alignment)
No specific time
Half-life
Hours (estimated)
~2 hours plasma; tissue effect days
04Side Effects & Safety
Parameter
Epitalon
Thymosin α-1
Injection site reaction
Mild irritation
Erythema, mild discomfort
Sleep architecture
Improved subjective sleep quality (anecdotal)
—
Cancer risk
Theoretical via telomerase activation in pre-malignant cells
No signal — used as adjuvant in oncology
Long-term safety
Limited Western RCT data
—
Pregnancy / OB
Avoid
Avoid
Antibody formation
Not reported
—
GI symptoms
—
Rare nausea
Fatigue
—
Common during initial weeks
Fever / flu-like
—
Mild interferon-like response possible
Autoimmune
—
Theoretical risk; caution in active autoimmune disease
Absolute Contraindications
Epitalon
- ·Pregnancy / breastfeeding
- ·Active malignancy or pre-malignant state
Thymosin α-1
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
- ·Concurrent immunosuppressant therapy (transplant patients)
Relative Contraindications
Epitalon
- ·Family history of cancer
Thymosin α-1
- ·Active autoimmune disease
- ·Severe immunocompromised state without supervision
05Administration Protocol
Parameter
Epitalon
Thymosin α-1
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.
Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.
2. Injection site
SQ — abdomen preferred. Rotate sites.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Timing
Pre-sleep preferred to align with pineal axis.
2× weekly, e.g. Monday + Thursday.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.
5. Needle
29–31G, 4–8 mm insulin syringe.
27–31G, 4–8 mm insulin syringe.